Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 21 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 21 versus PHILITH.
NORTREL 1/35-21 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
1 mg orally once daily
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive